Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Di Cianni, G.
Right arrow Articles by Del Prato, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Cianni, G.
Right arrow Articles by Del Prato, S.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:982-983, 2005
© 2005 by the American Diabetes Association, Inc.

Letters: Observations

Use of Insulin Glargine During the First Weeks of Pregnancy in Five Type 1 Diabetic Women

Graziano Di Cianni, MD, Laura Volpe, MD, Cristina Lencioni, MD, Kyriazoula Chatzianagnostou, MD, Ilaria Cuccuru, MD, Alessandra Ghio, MD, Luca Benzi, MD and Stefano Del Prato, MD

From the Department of Endocrinology and Metabolism, Section of Diabetes, University of Pisa, Pisa, Italy

Address correspondence to Dr. Graziano Di Cianni, Department of Endocrinology and Metabolism, Section of Diabetes and Metabolic Diseases, Ospedale di Cisanello, Via Paradisa, 2, I-56126 Pisa, Italy. E-mail: dicianni{at}immr.med.unipi.it

The long-acting analog glargine is a new insulin with 24-h persistence. This peculiar peakless action profile accounts for significant risk reduction for nocturnal hypoglycemia and a more stable daily plasma glucose profile (1,2). Only a few reports have described the use of insulin glargine during human pregnancy, so its use is not recommended at present. Animal studies have addressed the safety and efficacy of glargine during pregnancy, showing no direct effect on reproduction and embryo-fetal development (3). Recently, Devlin et al. (4) and Holstein et al. (5) reported the use of insulin glargine in two type 1 diabetic women; both cases were free of any pregnancy complications and with no direct effect on embryogenesis.

We report on five case subjects who used glargine during unplanned pregnancy (Table 1). All five diabetic women attended their first diabetes evaluation at our Outpatient Clinic between November 2002 and February 2004. None had evidence of retinopathy or autonomic neuropathy and they had normal urinary albumin excretion. They initiated glargine 5–12 months before conception because of frequent nocturnal hypoglycemia and suboptimal glycemic control. Insulin glargine was started as part of a basal-bolus regimen with an average dose of 25 ± 17 IU/day (range 14–56) given as a single predinner subcutaneous injection. The first diabetes assessment after commencement of pregnancy occurred at the 6th gestational week in three cases, while the remaining women were seen at the 8th and 12th week of gestation, respectively. Their HbA1c at that time was 7.3 ± 0.8%. Due to the lack of controlled data on the safety and efficacy of glargine in pregnant women, all patients were switched to NPH in the morning and bedtime, along with the usual premeal insulin therapy. After 2 weeks of the new insulin regimen, three women were started on continuous subcutaneous insulin infusion because optimal control could not be attained. In all five patients, strict glycemic control was achieved, with an average HbA1c of 6.0 ± 0.2% at the end of pregnancy. Pre-eclampsia developed in one patient at the 32nd week of gestation, and neither progression in retinopathy nor other microangiopatic complications were detected. Previous observations have reported that the use of glargine is associated with worsening eye disease in type 2 diabetic women (2). Babies (two males and three females) were delivered at a mean gestational age of 36.6 ± 1.1 weeks by cesarean section in all but one woman. Mean birth weight was 3,066 ± 898 g, with one baby >4 kg, whereas the other four babies’ weights were adequate for gestational age. There was neither major nor minor congenital malformation, and none of the babies had any complications during the postpartum period.


View this table:
[in this window]
[in a new window]
  		Table 1— Clinical characteristics of five type 1 diabetic pregnancies

 
Our experience is limited to a few subjects; nevertheless, all the observed women used insulin glargine from the preconception period to 6–12 weeks’ postconception. Hyperglycemia during the first 8 weeks of gestation, as clearly reported by Mills et al. (6), increases the risk of congenital anomalies. In our report, insulin glargine does not seem to affect embryo-fetal development in this critical period of embryogenesis. However, the small number of women and the early discontinuation of therapy with insulin glargine do not allow us to draw any final conclusion. Nevertheless, this observation, as well as other anecdotic observations, emphasizes the need for properly planned investigations.

References

  1. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA: Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 23:639–643, 2000[Abstract/Free Full Text]
  2. Bolli G, Owens DR: Insulin glargine. Lancet 356:443–445, 2000[Medline]
  3. Hofmann T, Horstmann G, Stammberger I: Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int J Toxicol 21:181–189, 2002[Medline]
  4. Devlin JT, Hothersall L, Wilkis JL: Use of insulin glargine during pregnancy in a type 1 diabetic woman (Letter). Diabetes Care 25:1095–1096, 2002[Free Full Text]
  5. Holstein A, Plaschke A, Egberts EH: Use of insulin glargine during embryogenesis in a pregnant woman with type 1 diabetes. Diabet Med 20:779–780, 2003[Medline]
  6. Mills JL, Baker L, Goldman AS: Malformations in infants of diabetic mothers occur before the seventh gestational week: implications for treatment. Diabetes 28:292–293, 1979[Abstract]
  7. Hare JW, White P: Gestational diabetes and the White classification. Diabetes Care 3:394–396, 1980

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
L. Jovanovic and D. J. Pettitt
Treatment With Insulin and Its Analogs in Pregnancies Complicated by Diabetes
Diabetes Care, July 1, 2007; 30(Supplement_2): S220 - S224.
[Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
A. L. Trujillo
Insulin Analogs and Pregnancy
Diabetes Spectr, April 1, 2007; 20(2): 94 - 101.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. M. Woolderink, A. J. van Loon, F. Storms, L. de Heide, and K. Hoogenberg
Use of Insulin Glargine During Pregnancy in Seven Type 1 Diabetic Women
Diabetes Care, October 1, 2005; 28(10): 2594 - 2595.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Dolci, M. Mori, and F. Baccetti
Use of Glargine Insulin Before and During Pregnancy in a Woman With Type 1 Diabetes and Addison's Disease
Diabetes Care, August 1, 2005; 28(8): 2084 - 2085.
[Full Text] [PDF]

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Di Cianni, G.
Right arrow Articles by Del Prato, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Cianni, G.
Right arrow Articles by Del Prato, S.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum